Hormonal background of the hypertension and fluid derangements associated with adrenocorticotrophic hormone treatment of infants.
We studied the hormonal background of the fluid derangements and arterial hypertension associated with adrenocorticotrophic hormone (ACTH) treatment for infantile spasms in ten infants aged 5-22 months. They received a 6 week course of (carboxymethyl-cellulose-)ACTH: 80 IU at 0800 hours daily in weeks 1-3, then tapering, and termination at the end of week 6. The infants showed large, variable increases in 24 h urine cortisol during treatment. The mean plasma cortisol concentration (24 h after ACTH injection) was not significantly increased, but was correlated with the relative dose of ACTH. The mean plasma aldosterone concentration decreased. No significant change occurred in plasma renin activity (PRA), or in the concentrations of renin substrate (RS) or arginine vasopressin (AVP). Seven infants developed arterial hypertension, which was severe in three. This severe hypertension was associated with the highest relative ACTH doses and the highest plasma RS and cortisol concentrations. In the group as a whole, systolic blood pressure correlated with plasma RS and cortisol concentrations, but not with the other parameters. At the end of treatment urine and plasma cortisol dropped below the pretreatment levels and stayed low for greater than 2 weeks. There was a sharp peak in PRA and plasma aldosterone concentration, and a decrease in plasma RS. Plasma AVP levels dropped markedly. The mean body weight increased sharply and urine flow decreased. Mean plasma electrolyte levels remained unaltered. The danger at termination of ACTH treatment appears to be associated with a sudden transition from hypercortisolism to hypocortisolism, activation of the renin-angiotensin-aldosterone axis, and suppression of AVP secretion.
Riikonen
R
R
Children's Hospital, University of Helsinki, Finland.
Simell
O
O
Dunkel
L
L
Santavuori
P
P
Perheentupa
J
J
D000324:Adrenocorticotropic Hormone / Q000009:adverse effects* / Q000627:therapeutic use; D001127:Arginine Vasopressin / Q000097:blood; D005260:Female; D006801:Humans; D006973:Hypertension / Q000139:chemically induced*; D007223:Infant; D008297:Male; D012084:Renin-Angiotensin System / Q000187:drug effects; D013036:Spasms, Infantile / Q000188:drug therapy* / Q000378:metabolism; D014882:Water-Electrolyte Balance / Q000187:drug effects*
D001127:Arginine Vasopressin; D000324:Adrenocorticotropic Hormone